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The 15th Congress on Immune Pathology and Orphan Disease held in Turin, Italy, on January, 20–22, 
2012, was especially dedicated to the following issues: 
 The intriguing connections between immune-mediated diseases, immunodeficiencies and 
lymphoproliferative disorders and the rationale for innovative treatments; 
 
 Novel diagnostic approaches to immunologic and rare diseases; 
 
 The expanding role of videocapillaroscopy in the diagnosis and clinical monitoring of systemic 
sclerosis-related disorders; 
 
 Identification criteria of high risk patients with antiphospholipid syndrome; 
 
 Algorithms of treatment of rheumatoid arthritis with TNF antagonists; 
 
 Cost–benefit balance of RA treatment in the era of biologic drugs. 
 
The traditional classification of diseases of the immune system that separates immunodeficiencies [1], 
allergy and hypersensitivity diseases, autoimmune diseases, and lymphoproliferative disorders is currently 
outdated. Many experimental observations and clinical data support the existence of a widespread 
overlapping. Baldovino et al. [2, present issue] reported on the most recent genetic and etiologic data 
linking common variable immunodeficiency (CVID) with some autoimmune diseases, and emphasized the 
need to systematically search for a CVID in patients with immune-mediated diseases showing deficiency 
in IgG, IgM or IgA levels. The authors also focused on the possible role of viral and bacterial infections as 
causative agents of autoimmune and inflammatory manifestations in CVID [3]. 
Many features link autoimmune disorders (AD) and lymphoproliferative disorders [4]. The risk of 
developing non-Hodgkin's lymphoma (NHL) in Sjögren's syndrome, rheumatoid arthritis and systemic 
lupus erythematosus has been found to be 4 to 40 folds greater than in the general population. B-cell 
activation and proliferation are part of AD and are essential factors for the onset of malignant cell clones in 
a deregulated immunological environment. Tarella's review [5, present issue] provides details on the main 
epidemiological features regarding NHL incidence in AD, the pathogenetic factors that favor lymphoma 
onset and some recent advances in therapeutic approaches that are effective in both autoimmune and 
malignant lymphoproliferative disorders. Indeed, targeting deregulated or malignant B-cells is the goal of 
some newly developed treatments. The prototype is the anti-CD20 monoclonal antibody, rituximab. It has 
substantially modified the prognosis of B-cell NHL [6] and is also an effective new therapeutic 
opportunity for some AD [7]. Similarly, intensified treatments with autologous hematopoietic stem cell 
transplant that were developed for high-risk lymphoma are now under advanced investigation for use in 
some refractory AD. The successful use of rituximab and ASCT in both AD and NHL further emphasizes 
the close link between these two entities. 
With regard to the novel diagnostic approaches to immunologic and rare diseases [8], lab-on-a-chip 
devices are analytic platforms that will open revolutionary opportunities in diagnostic testing [9]. They are 
completely automated devices which allow manipulation of small volumes of fluids and miniaturization of 
complex laboratory procedures onto small microchips. These analytical microsystems integrate various 
functional modules into a single device, sparing reagents and biologic samples, and delivering results in a 
fast turnaround time. In this special issue a variety of lab-on-a-chip devices developed for immunoassays 
and genomic testing that are especially dedicated to the diagnosis of rare diseases have been reviewed by 
Menegatti et al. [10, present issue] including those using multiplexed, miniaturized and ultra-sensitive 
technologies than can simultaneously identify multiple markers in the routine clinical setting of immuno-
mediated diseases. 
 
As far as the expanding role of nailfold videocapillaroscopy is concerned, this technique has already been 
widely accepted as the most valuable tool for the early diagnosis of disorders related to systemic sclerosis 
[11] and [12]. However, its potential in monitoring disease progression and especially its predictive value 
of clinical complications is still debated. Capillaroscopic abnormalities are susceptible to significant 
change during patient follow-up. Rossi et al. [13, present issue] discuss the usefulness of scoring 
capillaroscopic alterations, which, albeit time-consuming, should be systematically used in order to 
monitor microangiopathy. 
 
With regard to the workshop on high risk patients with antiphospholipid syndrome, in order to better 
define the clinical setting of thrombotic recurrences in thrombotic patients with APS, a systematic review 
of the literature as of 1999, including 8 cohort studies and 6 intervention studies, was carried out by 
Bazzan et al. [14, present issue]. Thrombotic recurrences, bleeding events, therapeutic strategies, 
antiphospholipid (aPL) profile, and possible inherited or acquired risk factors were evaluated. Emerging 
risk factors for thrombotic recurrences included the aPL “profile” (i.e., triple positivity: positive lupus 
anticoagulant, anticardiolipin and anti β2-glycoptrotein I antibodies), discontinuation of oral anticoagulant 
therapy (OAT), and associated general risk factors and inherited thrombophilia. APS vascular patients with 
high risk aPL profiles were found to have a high recurrence rate in spite of correct OAT treatment [15]. 
Aspirin did not significantly affect the incidence of thrombotic events in these APS patients. Pengo et al. 
[16, present issue] emphasize that the triple positivity identifies a highly pathogenic autoantibody (an anti 
domain I of β2-glycoptrotein I, which was proven to retain lupus anticoagulant activity). Patients and 
carriers with this profile carry a much higher risk of thrombosis and miscarriage than APS patients with 
positivity for only one test. Thus, very different risk categories exist among patients with APS as well as 
among carriers of aPL. Clinical studies and interventional trials should first take these high risk subjects 
into consideration [17]. 
Several sessions of the Turin Meeting were dedicated to the changing therapeutic strategies of immune-
mediated diseases in the era of biologic drugs, and the staggering financial consequences of the expanding 
indications of these innovative approaches. 
Treatments that were available prior to the advent of biological drugs could not control joint destruction 
and progression of disability in patients with rheumatoid arthritis (RA). Randomized clinical trials have 
shown that the five currently available TNF blockers improve the signs and symptoms of both early RA 
and long-standing RA and other inflammatory arthritides, that they prevent radiographic progression, and 
improve the patients' health-related quality of life. Although biologic drugs dramatically improve the 
quality of life of RA patients, they multiply direct medical costs. Indeed, annual treatment costs for RA 
patients rose from 4000 to 12,000 Euro over a five-year period (from 2000 to 2005). However, this 
estimate referred to direct costs alone. Modena et al. [18, present issue] analyzed the costs related to RA 
[19] and [20] considering both direct (pharmacological, surgical and rehabilitative) and indirect costs 
(including loss of work productivity), and, intangible costs (cost of suffering due to the deterioration of the 
quality of life of both patients and their families). The main factors affecting the best cost-effectiveness in 
the management of RA in clinical practice included the speed of action of the drug, the safety profile of the 
various drugs, and “tight control” in patient management. “Tight control” has been defined as a treatment 
strategy tailored to the individual RA patient, aimed at achieving a predefined level of low disease activity 
or remission within a defined period of time [21]. In order to pursue this goal, Epis et al. [ 22, present 
issue] emphasize the need for continuous monitoring of disease activity with early therapeutic adjustments, 
or switching to other therapeutic options. 
Leardini et al. [23, present issue] carried out a detailed head to head comparison of different biological 
therapies for RA. They analyzed not only the costs of purchasing and administering the drug, but also 
those related to acute and chronic complications of therapy, especially infections [24]. Notably, contrary to 
widespread opinion concerning the higher cost of intravenous therapies as compared to other routes of 
administration due to the use of hospital facilities, the authors highlighted a 7.3% difference in favor of 
intravenous versus subcutaneous biologics. Leardini et al. also emphasized the difference between ex-
factory prices, which are usually considered in pharmacoeconomic studies, and actual costs, which are 
about one third lower, arguing the superiority of innovative therapies in the management of RA. 
With regard to the other immune-mediated diseases that biologic drugs are now being indicated for, 
glomerulonephritis (GN) accounts for 10%–20% of the total incident cases of end stage renal disease 
(ESRD), and is the third most common cause of ESRD after diabetes and hypertension in western 
countries. Research into the underlying mechanisms of several immune-mediated glomerular diseases has 
revealed the importance of auto-antibodies in these disease processes. In the last forty years, empirical 
treatment has been based upon the use of corticosteroids and/or immunosuppressive drugs. Pani analyzed 
[25, present issue] the risk-to-benefit balance of steroids and conventional immunosuppressive regimens 
focusing on idiopathic nephrotic syndrome (INS) and ANCA associated vasculitis [26], [27], [28] and 
[29]. Almost 95% of children affected by minimal change disease achieve remission of proteinuria within 
4 to 8 weeks of prednisone administration. In adults with focal segmental glomerulosclerosis, prednisone 
induces at least partial remission in the majority of patients. More than 65% of patients with idiopathic 
membranous nephropathy reach complete or partial remission with a 6-month course of therapy alternating 
glucocorticoids with alkylating agents. Glucocorticoids plus cyclophosphamide, and, on occasion, 
plasmapheresis are effective in 70%–90% percent of patients with ANCA-associated vasculitis. However, 
although very effective, especially in the acute phase, corticosteroids, nucleotide synthesis inhibitors, 
alkylating agents and calcineurin inhibitors have severe side-effects. Therefore, we need drugs with more 
targeted mechanisms of action and fewer side effects in order to overcome the current limits of 
conventional immunosuppression [30]. Given the understanding that in several renal diseases, such as 
ANCA-associated vasculitis, mixed cryoglobulinemia, membranous nephropathy and lupus nephritis, 
auto-antibodies have been implicated either in direct glomerular injury or as correlates with disease 
activity, rituximab has emerged as a potent option for many immune-mediated glomerulopathies. Based on 
recent large clinical trials, it has been FDA-approved for the treatment of ANCA-associated vasculitis and 
continues to be studied in off-label usage for many glomerular diseases, including membranous 
nephropathy, lupus nephritis, and mixed cryoglobulinemia [31], [32], [33], [34], [35], [36], [37], [38], [39], 
[40] and [41]. It has been used as a treatment in nephrotic syndrome in children and adults, including both 
minimal change disease and focal segmental glomerulosclerosis. Kattah et al. [42, present issue] discuss 
the current state of anti-CD20 therapy in several glomerular disease processes, and show that, given its 
efficacy, tolerability and safety profile as compared to conventional immunosuppressive regimens, RTX is 
rapidly emerging as an alternative treatment strategy in glomerular diseases. 
As stated before for RA, major concerns are represented by the financial impact of these new therapeutic 
approaches, but apart from costs, the question is “should biological therapy be continued indefinitely”? 
Leardini et al. [23, present issue] just touched on this issue by examining the general safety of biologics. In 
our mind the impact of the possible adverse effects of conventional and novel drugs should be analyzed in 
the long term similar to the epidemiologic approach to second tumors occurring several decades after the 
chemotherapy of childhood cancer. In this context, a new concept of biologic therapy is emerging, at least 
for immune diseases that (although chronic in the clinical course) are mainly characterized by time-limited 
acute flares, i.e., short-intensive courses of combined conventional and biological therapy without 
maintenance immunosuppressive treatment [43] and [44]. This could limit both the costs and the sequelae 
of prolonged immunosuppression. 
 
 
References 
[1] H. Chapel, M. Lucas, M. Lee, J. Bjorkander, D. Webster, B. Grimbacher et al. Common variable 
immunodeficiency disorders: division into distinct clinical phenotypes 
Blood, 112 (2) (2008), pp. 277–286 [Lug 15] 
 
[2] S. Baldovino, D. Montin, S. Martino, S. Sciascia, E. Menegatti, D. Roccatello . Common variable 
immunodeficiency: Crossroads between infections, inflammation and autoimmunity 
Autoimmun Rev, 12 (8) (2013), pp. 796–801 
 
[3] D.H. Dreyfus Autoimmune disease: a role for new anti-viral therapies Autoimmun Rev, 11 (2) (2011), 
pp. 88–97 
[4]Y. Tomer, Y. Sherer, Y. Shoenfeld.Autoantibodies, autoimmunity and cancer (review). Oncol Rep, 5 
(1998), pp. 753–761 
[5] C. Tarella, A. Gueli, M. Ruella, A. Cignetti. Lymphocyte transformation and autoimmune disorders. 
Autoimmun Rev, 12 (8) (Mar 2013), pp. 802–813 
 [6] C. Tarella, M. Zanni, M. Magni, F. Benedetti, C. Patti, T. Barbui et al. Rituximab improves the 
efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell 
lymphoma: a multicenter Gruppo Italiano Terapie Innnovative Nei Linfomi survey. J Clin Oncol, 26 
(2008), pp. 3166–3175 
 [7] I. Sanz. Indications of rituximab in autoimmune diseases. Drug Discov Today Ther Strateg, 6 (2009), 
pp. 13–19 
[8] S. Sciascia, L. Ceberio, C. Garcia-Fernandez, D. Roccatello, Y. Karim, M.J. Cuadrado. Systemic lupus 
erythematosus and infections: clinical importance of conventional and upcoming biomarkers. Autoimmun 
Rev, 12 (2) (2012 Dec), pp. 157–163 
[9] S.L. Marasso, E. Giuri, G. Canavese, R. Castagna, M. Quaglio, I. Ferrante et al.A multilevel lab on 
chip platform for DNA analysis. Biomed Microdevices, 13 (2011), pp. 19–27 
[10] E. Menegatti, D. Berardi, M. Messina, I. Ferrante, O. Giachino, B. Spagnolo et al. Lab-on-chip. 
Emerging analytical platforms for immune mediated diseases. Autoimmun Rev (2012 Dec 3) [Epub ahead 
of print] 
[11] F. Galluccio, M. Matucci-Cerinic. Two faces of the same coin: Raynaud phenomenon and digital 
ulcers in systemic sclerosis. Autoimmun Rev, 10 (5) (Mar 2011), pp. 241–243 
[12] C. Chighizola, Y. Shoenfeld, P.L. Meroni. Systemic sclerosis. Introduction Autoimmun Rev, 10 (5) 
(Mar 2011), pp. 239–240 
[13] D. Rossi, A. Russo, E. Manna et al. The role of nail-videocapillaroscopy in early diagnosis of 
scleroderma. Autoimmun Rev (2012 Dec 4) [Epub ahead of print] 
[14] M. Bazzan, A. Vaccarino, S. Stella, M.T. Bertero, R. Carignola, B. Montaruli et al. Thrombotic 
recurrences and bleeding events in APS vascular patients: A review from the literature and a comparison 
with the APS Piedmont cohort. Autoimmun Rev, 12 (8) (2013), pp. 826–831 
[15] V. Pengo, G. Ruiz-Irastorza, G. Denas, L. Andreoli, M. Khamashta, A. Tincani. High intensity 
anticoagulation in the prevention of the recurrence of arterial thrombosis in antiphospholipid syndrome. 
“PROS” and “CONS”Autoimmun Rev, 22 (Oct 2011) [epub ahead of print] 
[16] V. Pengo, A. Banzato, G. Denas, J.S. Padayattil, E. Bison, A. Hoxha et al. Correct laboratory 
approach to APS diagnosis and monitoring. Autoimmun Rev, 12 (8) (2013), pp. 832–834 
 [17] T. Scoble, S. Wijetilleka, M.A. Khamashta. Management of refractory anti-phospholipid syndrome 
Autoimmun Rev, 10 (2011), pp. 669–673 
 [18] V. Modena, G. Bianchi, D. Roccatello . Cost-effectiveness of biologic treatment for rheumatoid 
arthritis in clinical practice: An achievable target? Autoimmun Rev, 12 (8) (2013), pp. 835–838 
[19] A.C. Rat, M.C. Boissier. Rheumatoid arthritis: direct and indirect costs. Joint Bone Spine, 71 (6) (Nov 
2004), pp. 518–524 
[20]F. Guillemin, S. Durieux, J.P. Daures, A. Lafuma, A. Saraux, J. Sibilia et al.Costs of rheumatoid 
arthritis in France: a multicenter study of 1109 patients managed by hospital-based rheumatologists. J 
Rheumatol, 31 (2004), pp. 1297–1304 
[21]D.L. Scott, A. Kowalczyk. Clinical trials: tight control in early RA pays off in the long run. Nat Rev 
Rheumatol, 6 (2010), pp. 623–624 
[22]O.M. Epis, L. Giacomelli, S. Deidda, E. Bruschi et al.Tight control applied to the biological therapy of 
rheumatoid arthritis. Autoimmun Rev (2012 Dec 3) [Epub ahead of print] 
[23] G. Leardini, C. Rigon. The impact of the profile of biologics on treatment costs. Autoimmun Rev, 12 
(8) (2013), pp. 842–847 
[24]G. Leardini, F. Salaffi, R. Montanelli, S. Gerzeli, B. CanesiA multicenter cost-of-illness study on 
rheumatoid arthritis in Italy. Clin Exp Rheumatol, 20 (4) (2002), pp. 505–515 
[25] A. Pani. Conventional therapy of immune-mediated glomerular diseases. Autoimmun Rev (2012 Dec 
3) [Epub ahead of print] 
[26]C. Ponticelli, P. Zucchelli, P. Passerini, B. Cesana, F. Locatelli, S. Pasquali et al. A 10-year follow-up 
of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney 
Int, 48 (1995), pp. 1600–1604 
[27] C. Ponticelli, P. Altieri, F. Scolari, P. Passerini, D. Roccatello, B. Cesana et al. A randomized study 
comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in 
idiopathic membranous nephropathy. J Am Soc Nephrol, 9 (1998), pp. 444–450 
[28] S.M. Korbet. Treatment of primary focal segmental glomerulosclerosis. Kidney Int, 62 (2002), pp. 
2301–2310 
[29]C. Mukhtyar, O. Flossmann, B. Hellmich, P. Bacon, M. Cid, J.W. Cohen-Tervaert et al.Outcomes 
from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the 
European League Against Rheumatism Systemic Vasculitis Task Force. Ann Rheum Dis, 67 (7) (2008), 
pp. 1004–1010 
[30] A.Z. Barabas, C.D. Cole, R.M. Graeff, R. Lafreniere, D.M. Weir. The role of autoimmunologists in 
investigating and treating autoimmune disorders. Autoimmun Rev, 10 (3) (Jan 2011), pp. 166–170 
[31] J.H. Stone, P.A. Merkel, R. Spiera, P. Seo, C.A. Langford, G.S. Hoffman et al. Rituximab versus 
cyclophosphamide for ANCA-associated vasculitis N Engl J Med, 363 (3) (2010), pp. 221–232 
[32]U. Specks, J.H. Stone. Long-term efficacy and safety results of the RAVE trial. Clin Exp Immunol, 
2011 (164) (2011), p. 65 
[33]D. Roccatello, S. Sciascia, D. Rossi, M. Alpa, C. Naretto, A. Russo et al. Long-term effects of 
rituximab added to cyclophosphamide in refractory patients with vasculitis Am J Nephrol, 34 (2) (2011), 
pp. 175–180 
[34]M.J. Leandro, G. Cambridge, J.C. Edwards, M.R. Ehrenstein, D.A. Isenberg.B-cell depletion in the 
treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients 
Rheumatology (Oxford), 44 (12) (2005), pp. 1542–1545 
[35] J.T. Merrill, C.M. Neuwelt, D.J. Wallace, J.C. Shanahan, K.M. Latinis, J.C. Oates et al. Efficacy and 
safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, 
double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum, 62 
(1) (2010), pp. 222–233 
[36]T.Y. Lu, K.P. Ng, G. Cambridge, M.J. Leandro, J.C. Edwards, M. Ehrenstein et al. A retrospective 
seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University 
College London Hospital: the first fifty patients. Arthritis Rheum, 61 (4) (2009), pp. 482–487 
[37] D. Roccatello, S. Sciascia, D. Rossi, M. Alpa, C. Naretto, S. Baldovino et al. Intensive short-term 
treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe 
cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy. Nephrol Dial 
Transplant, 26 (12) (2011), pp. 3987–3992 
[38]G. Remuzzi, C. Chiurchiu, M. Abbate, V. Brusegan, M. Bontempelli, P. Ruggenenti. Rituximab for 
idiopathic membranous nephropathy. Lancet, 360 (9337) (2002), pp. 923–924 
[39]F.C. Fervenza, F.G. Cosio, S.B. Erickson, U. Specks, A.M. Herzenberg, J.J. Dillon et al. Rituximab 
treatment of idiopathic membranous nephropathy. Kidney Int, 73 (1) (2008), pp. 117–125 
[40]D. Roccatello, S. Baldovino, D. Rossi, O. Giachino, M. Mansouri, C. Naretto et al. Rituximab as a 
therapeutic tool in severe mixed crioglobulinemia. Clin Rev Allergy Immunol, 34 (1) (2008), pp. 111–117 
[41] S. De Vita, L. Quartuccio, M. Isola, C. Mazzaro, P. Scaini, M. Lenzi et al. A randomized controlled 
trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum, 64 (3) (2012), 
pp. 843–853 
[42] C. Ferri, P. Cacoub, C. Mazzaro, D. Roccatello, P. Scaini, M. Sebastiani et al.Treatment with 
rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and 
review of the literature. Autoimmun Rev, 11 (1) (2011), pp. 48–55.  
[43] A.G. Kattah, F.C. Fervenza, D. Roccatello. Rituximab-based novel strategies for the treatment of 
immune-mediated glomerular diseases. Autoimmun Rev, 12 (8) (2013), pp. 854–859 
[44]E. Leah. Rituximab for refractory SLE patients reach lasting remission with short-term regimen. Nat 
Rev Rheumatol, 7 (2011), p. 312  
 
 
